Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
Regeneron Pharmaceuticals (NASDAQ: REGN) has scheduled its third quarter 2025 financial and operating results announcement for Tuesday, October 28, 2025, before U.S. market opening. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the event through a webcast on Regeneron's investor relations website. For telephone participation, advance registration is required through a provided link. A replay and transcript will be available on the company's website for at least 30 days following the event.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha fissato l'annuncio dei risultati finanziari e operativi del terzo trimestre 2025 per martedì 28 ottobre 2025, prima dell'apertura dei mercati statunitensi. L'azienda organizzerà una conference call e una webcast alle 8:30 AM Eastern Time nello stesso giorno. Gli investitori possono partecipare all'evento tramite una webcast sul sito di Relazioni con gli Investitori di Regeneron. Per partecipare telefonicamente, è necessaria la registrazione anticipata tramite il link fornito. Una replica e la trascrizione saranno disponibili sul sito dell'azienda per almeno 30 giorni dopo l'evento.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha programado el anuncio de resultados financieros y operativos del tercer trimestre de 2025 para el martes 28 de octubre de 2025, antes de la apertura del mercado de EE. UU. La compañía realizará una conferencia telefónica y un webcast a las 8:30 a.m. hora del Este ese mismo día. Los inversionistas pueden acceder al evento a través de un webcast en el sitio de relaciones con inversionistas de Regeneron. Para participar por teléfono, se requiere registro previo mediante el enlace proporcionado. Una repetición y la transcripción estarán disponibles en el sitio web de la empresa durante al menos 30 días después del evento.
Regeneron Pharmaceuticals (NASDAQ: REGN)가 2025년 3분기 재무 및 운영 실적 발표를 2025년 10월 28일 화요일에 미국 시장 개장 전에 예정했습니다. 회사는 같은 날 동부 시간 8:30 AM에 컨퍼런스 콜과 웹캐스트를 개최합니다. 투자자들은 Regeneron의 투자자 관계 웹사이트의 웹캐스트를 통해 이벤트에 접속할 수 있습니다. 전화 참여를 위해서는 제공된 링크를 통한 사전 등록이 필요합니다. 재방송과 대본은 이벤트 후 최소 30일간 회사 웹사이트에서 이용 가능합니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a programmé l'annonce des résultats financiers et opérationnels du troisième trimestre 2025 pour le mardi 28 octobre 2025, avant l'ouverture des marchés américains. L'entreprise tiendra une conférence téléphonique et un webcast à 8 h 30, heure de l'Est le même jour. Les investisseurs peuvent accéder à l'événement via un webcast sur le site relations investisseurs de Regeneron. Pour participer par téléphone, une inscription préalable est requise via le lien fourni. Un enregistrement et une transcription seront disponibles sur le site de l'entreprise pendant au moins 30 jours après l'événement.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat die Ankündigung der Finanzergebnisse und operativen Ergebnisse für das dritte Quartal 2025 auf Dienstag, den 28. Oktober 2025 festgelegt, vor der Eröffnung des US-Marktes. Das Unternehmen wird am selben Tag eine Konferenzschaltung und einen Webcast um 8:30 Uhr Eastern Time veranstalten. Investoren können über den Webcast auf der Investor-Relations-Website von Regeneron an der Veranstaltung teilnehmen. Für eine telefonische Teilnahme ist eine vorherige Registrierung über den bereitgestellten Link erforderlich. Eine Wiederholung und ein Transkript werden für mindestens 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
حدّدت Regeneron Pharmaceuticals (ناسداك: REGN) إعلان النتائج المالية والتشغيلية للربع الثالث من 2025 في الثلاثاء 28 أكتوبر 2025، قبل افتتاح السوق الأمريكية. ستعقد الشركة مكالمة مؤتمريّة وبثًا مباشرًا عبر الويب في الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة في اليوم نفسه. يمكن للمستثمرين الوصول إلى الحدث من خلال بث مباشر على موقع علاقات المستثمرين لشركة Regeneron. للمشاركة عبر الهاتف، يلزم التسجيل المسبق عبر الرابط المقدم. سيكون هناك إعادة عرض ونصّ متاحان على موقع الشركة لمدة لا تقل عن 30 يومًا بعد الحدث.
Regeneron Pharmaceuticals（纳斯达克股票代码：REGN）已将2025年第三季度财务与经营业绩公告定于2025年10月28日，星期二，在美国市场开盘前。公司将于同日举行美东时间上午8:30的电话会和网络广播。投资者可通过 Regeneron 投资者关系网站的网络广播参与活动。若以电话参与，需要通过提供的链接进行事先登记。活动结束后，公司网站将提供回放及文字记录，至少保留30天。
- None.
- None.
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
When will Regeneron (REGN) report Q3 2025 earnings?
What time is Regeneron's Q3 2025 earnings call?
How can investors access Regeneron's Q3 2025 earnings call?
How long will Regeneron's Q3 2025 earnings call replay be available?
